πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11185554

Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease

The Board of Regents of the University of Texas System Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11186577

Vasopressin receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. Β· Granted Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11179370

Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions,

Jenrin Discovery, LLC Β· Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11173118

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Heron Therapeutics, Inc. Β· Granted Tue Nov 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155523

Biphenyl compound as CCR2/CCR5 receptor antagonist

Medshine Discovery Inc. Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11154556

Methods of treating solid tumors with CCR2 antagonists

The Regents of the University of California Β· Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11141452

Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11136315

CXCR2 antagonist

Medshine Discovery Inc. Β· Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124504

Kappa opioid receptor antagonists and products and methods related thereto

BLACKTHORN THERAPEUTICS, INC. Β· Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124489

EPAC antagonists

The Board of Regents of the University of Texas System Β· Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11111272

Ξ±4Ξ±7 peptide monomer and dimer antagonists

Protagonist Therapeutics, Inc. Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11111270

Inhibitor of apoptosis protein (IAP) antagonists

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11104730

Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084865

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11078201

Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antag

Nimbus Saturn, Inc. Β· Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11077108

Allosteric corticotropin-releasing factor receptor 1 (CRFR1) antagonists that decrease p-t

The Regents of the University of California Β· Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066458

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034768

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034694

Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 anta

Nimbus Saturn, Inc. Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033539

Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic re

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11033554

Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11026920

Use of NK-1 receptor antagonist serlopitant in pruritus

Vyne Therapeutics Inc. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11026997

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11028085

Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 anta

Nimbus Saturn, Inc. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted